by elasmogen | Dec 2, 2022 | Publications
Obinna C. Ubah, Eric W. Lake, Gihan S. Gunaratne, Joseph P. Gallant, Marie Fernie, Austin J. Robertson, Jonathan S. Marchant, Tyler D. Bold, Ryan A. Langlois, William E. Matchett,Joshua M. Thiede, Ke Shi, Lulu Yin, Nicholas H. Moeller, Surajit Banerjee, Laura...
by elasmogen | May 18, 2022 | News
Aberdeen, Scotland, 18 May 2022: Elasmogen – a biopharmaceutical company discovering and developing new therapeutics using its unique soloMERTM platform – has secured £8 million investment. The funding round was led by BGF and Scottish National Investment Bank (The...
by elasmogen | May 18, 2022 | Team
Keith has been an Investor at BGF since 2015 leading investments across the North of Scotland. BGF are a £2.5bn fund supporting earlier stage and established private businesses, and smaller listed companies in the UK. Prior to joining BGF, Keith was an Investment...
by elasmogen | May 18, 2022 | Team
Jane has over 30 years’ experience in the life science industry across biotech, pharma and agrochemicals. She is currently Chair of Spirea and PharmEnable and an NED at Elasmogen, Macomics and Nanosyrinx. Her past roles include Chief Business Officer at F-star, Vice...
by elasmogen | Dec 17, 2021 | News
MADISON – Small, unique antibody-like proteins known as VNARs derived from the immune systems of sharks can prevent the virus that causes COVID-19, its variants, and related coronaviruses from infecting human cells, according to a new study published Dec. 16. The new...
